DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: etoposide
Drug: nelfinavir mesylate
Genetic: protein expression analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: biopsy
Radiation: radiation therapy

First Posted Date: 2008-01-09

Last Posted Date: 2020-04-24

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 55

Registration Number: NCT00589056

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: docetaxel
Drug: sorafenib tosylate

First Posted Date: 2008-01-09

Last Posted Date: 2022-02-17

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 18

Registration Number: NCT00589420

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: bortezomib
Drug: hydroxychloroquine

First Posted Date: 2007-12-06

Last Posted Date: 2020-02-07

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 25

Registration Number: NCT00568880

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Bevacizumab, Abraxane

First Posted Date: 2007-05-14

Last Posted Date: 2020-04-09

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 5

Registration Number: NCT00472693

Locations: 🇺🇸
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States

Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI
Drug: "Prophylactic" delayed ADLI
Drug: "Prophylactic" delayed activated donor lymphocyte infusion

First Posted Date: 2006-09-12

Last Posted Date: 2019-07-12

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 18

Registration Number: NCT00374933

Locations: 🇺🇸
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States

Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma

Phase 2

Terminated

Conditions: Rectal Cancer

Interventions: Drug: Capecitabine, Oxaliplatin and Cetuximab
Radiation: Radiation

First Posted Date: 2006-07-18

Last Posted Date: 2020-04-09

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 6

Registration Number: NCT00353457

Study of Bexarotene in Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: AML
Acute Myeloid Leukemia

First Posted Date: 2006-04-19

Last Posted Date: 2016-06-08

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 54

Registration Number: NCT00316030

Locations: 🇺🇸
Abramson Cancer Center of University of Pennsylvania, Philadelphia, Pennsylvania, United States

Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2005-08-10

Last Posted Date: 2016-02-19

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 22

Registration Number: NCT00128635

Locations: 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham, Birmingham, Alabama, United States

and more 1 locations

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2005-04-06

Last Posted Date: 2014-09-17

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 30

Registration Number: NCT00107211

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Gene Therapy in Treating Patients With Primary Brain Tumors

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-07-29

Last Posted Date: 2019-03-13

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT00002824

Locations: 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy